Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5905459 | 0.90 | CHRNA7 (0.47) | KDM4ECHRNA7DRD2HRH3SLC6A4 | |
| SCHEMBL5904992 | 0.90 | CHRNA7 (0.47) | KDM4ECHRNA7DRD2HRH3SLC6A4 | |
| SCHEMBL5905509 | 0.89 | HRH3 (0.47) | KDM4ECHRNA7DRD2HRH3SLC6A4 | |
| SCHEMBL5905546 | 0.89 | HRH3 (0.47) | KDM4ECHRNA7DRD2HRH3SLC6A4 | |
| SCHEMBL5905062 | 0.88 | HRH3 (0.48) | KDM4ECHRNA7DRD2HRH3SLC6A4 | |
| SCHEMBL5284002 | 0.88 | HRH3 (0.48) | KDM4ECHRNA7DRD2HRH3SLC6A4 | |
| SCHEMBL5905692 | 0.88 | CHRNA7 (0.43) | KDM4ECHRNA7DRD2HRH3SLC6A4 | |
| SCHEMBL5242490 | 0.87 | CHRNA7 (0.48) | KDM4ECHRNA7DRD2HRH3SLC6A4 | |
| SCHEMBL5904941 | 0.87 | CHRNA7 (0.48) | KDM4ECHRNA7DRD2HRH3SLC6A4 | |
| SCHEMBL5905534 | 0.86 | CHRNA7 (0.47) | KDM4ECHRNA7DRD2HRH3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | NEUROGEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | MCHR1, MCHR2, PRLHR | KDM4E 1610/4885CHRNA7 403/4885DRD2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.